Iovance Biotherapeutics, Inc. Detailed Financials
Full historical quarterly statements
| Metric | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 71.4M | 86.8M | 67.5M | 60.0M | 49.3M | 73.7M | 58.6M | 31.1M |
| Cost of Goods Sold | 1.0M | -100.5M | 1.4M | 56.7M | 49.7M | 45.5M | 39.8M | 31.4M |
| Gross Profit | 70.4M | 187.3M | 66.0M | 3.3M | -417K | 28.2M | 18.7M | -262K |
| R&D Expenses | 62.5M | 68.9M | 75.2M | 79.4M | 76.9M | 72.2M | 68.2M | 62.1M |
| Operating Expenses | 151.5M | 260.8M | 160.9M | 117.1M | 120.8M | 114.7M | 107.8M | 101.7M |
| Operating Income | -81.0M | -73.5M | -94.9M | -113.8M | -121.2M | -86.6M | -89.1M | -101.9M |
| Other Income / Gains | 1.3M | 1.7M | 1.2M | 4.1M | 3.2M | 9.6M | 4.0M | 3.4M |
| Net Income | -79.0M | -71.9M | -91.3M | -111.7M | -116.2M | -78.6M | -83.5M | -97.1M |
| EPS (Diluted) | -0.19 | -0.15 | -0.25 | -0.33 | -0.36 | -0.26 | -0.28 | -0.34 |
| Reported Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Gross Profit Ratio | 0.986 | 2.159 | 0.979 | 0.055 | -0.008 | 0.382 | 0.32 | -0.008 |
| General And Administrative Expenses | 0 | 0 | 0 | 0 | 10.6M | 0 | 39.6M | 0 |
| Selling And Marketing Expenses | 0 | 0 | 0 | 0 | 33.3M | 0 | 0 | 0 |
| Selling General And Administrative Expenses | 38.9M | 36.1M | 34.6M | 37.7M | 43.9M | 42.5M | 39.6M | 34.2M |
| Other Expenses | 50.0M | 155.8M | 51.2M | 0 | 0 | 0 | -1K | 5.4M |
| Cost And Expenses | 152.5M | 160.2M | 162.4M | 173.7M | 170.5M | 160.3M | 147.6M | 133.0M |
| Interest Income | 1.3M | 7.3M | 0 | 4.1M | 3.2M | 9.6M | 4.0M | 3.4M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation And Amortization | 8.5M | 3.9M | 9.0M | 11.9M | 11.1M | 11.7M | 11.1M | 10.9M |
| Ebitda | -71.2M | -67.8M | -84.7M | -97.7M | -106.9M | -65.3M | -77.9M | -87.7M |
| Ebitdaratio | -0.996 | -0.781 | -1.255 | -1.63 | -2.168 | -0.886 | -1.331 | -2.819 |
| Operating Income Ratio | -1.135 | -0.847 | -1.407 | -1.898 | -2.458 | -1.175 | -1.521 | -3.276 |
| Income Before Tax | -79.7M | -71.7M | -93.7M | -109.7M | -118.0M | -77.0M | -85.1M | -98.6M |
| Income Before Tax Ratio | -1.116 | -0.827 | -1.388 | -1.829 | -2.392 | -1.045 | -1.453 | -3.168 |
| Income Tax Expense | -665K | 184K | -2.4M | 2.0M | -1.8M | 1.6M | -1.5M | -1.5M |
| Net Income Ratio | -1.107 | -0.829 | -1.353 | -1.862 | -2.355 | -1.066 | -1.427 | -3.122 |
| Epsdiluted | -0.19 | -0.15 | -0.25 | -0.33 | -0.36 | -0.26 | -0.28 | -0.34 |
| Weighted Average Shs Out | 418.5M | 407.0M | 364.0M | 334.5M | 322.9M | 304.9M | 303.3M | 284.8M |
| Weighted Average Shs Out Dil | 418.5M | 407.0M | 364.0M | 334.5M | 322.9M | 304.9M | 303.3M | 284.8M |